Discover 764 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 764
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Washington D.C. DC, Fairfax VA, Baltimore MD, Newark DE,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase3, Recruiting
Active & Responsive
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
for
Advanced Esophageal Adenocarcinoma,
Location: Washington D.C. DC, Newark DE, Mechanicsburg PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06203600
Phase2, Phase3, Recruiting
Active & Responsive
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Location: Washington D.C. DC, Bethesda MD, Baltimore MD,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03816345
Phase1, Recruiting
Active & Responsive
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
for
Cervical Cancer, Metastatic Cervical Cancer
Location: Washington D.C. DC, Hackensack NJ, Augusta GA
Sponsor: Georgetown University
Sex: Female
Age: 18+
Code: NCT04865887
Phase2, Recruiting
Active & Responsive
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
for
Chondral Defect, Articular Cartilage Defect
Location: Washington D.C. DC, Charlottesville VA, Durham NC,
Sponsor: Vericel Corporation
Sex: All
Age: 17 - 65
Code: NCT06915233
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
for
Metastatic Colorectal Adenocarcinoma,
Location: Washington D.C. DC, Baltimore MD, Atlanta GA, Aurora CO
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07147231
Phase1, Phase2, Recruiting
Active & Responsive
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
for
Extensive Stage Lung Small Cell Carcinoma,
Location: Washington D.C. DC, Baltimore MD, Richmond VA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06287775
Phase1, Phase2, Recruiting
Active & Responsive
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Location: Washington D.C. DC, Rockville MD, Philadelphia PA,
Sponsor: Electra Therapeutics Inc.
Sex: All
Age: 6+
Code: NCT05416307
Phase2, Phase3, Recruiting
Active & Responsive
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
for
Sickle Cell Disease
Location: Washington D.C. DC, Baltimore MD, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 12 - 70+
Code: NCT06439082
Phase3, Recruiting
Active & ResponsiveNew
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
for
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma,
Location: Washington D.C. DC
Sponsor: Children's National Research Institute
Sex: All
Age: 3 - 25
Code: NCT07664176
Phase1, Recruiting
Active & ResponsiveNew
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
for
Neurofibromatosis 1, Plexiform Neurofibroma
Location: Washington D.C. DC, Philadelphia PA, Boston MA,
Sponsor: Girish Dhall, MD
Sex: All
Age: 16+
Code: NCT06502171
Phase1, Recruiting
Active & Responsive
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
for
Neuroblastoma, Sarcoma
Location: Washington D.C. DC, The Bronx NY, Columbus OH,
Sponsor: Nationwide Children's Hospital
Sex: All
Age: 1 - 40
Code: NCT05135975
Phase2, Recruiting
Active & Responsive
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders